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Endogenous c-Myc is essential for p53-induced
apoptosis in response to DNA damage in vivo
TJ Phesse1,2,3,4,9, KB Myant5,9, AM Cole5,9, RA Ridgway5,9, H Pearson1, V Muncan6, GR van den Brink6, KH Vousden5, R Sears7,
LT Vassilev8, AR Clarke1 and OJ Sansom*,5
Recent studies have suggested that C-MYC may be an excellent therapeutic cancer target and a number of new agents targeting
C-MYC are in preclinical development. Given most therapeutic regimes would combine C-MYC inhibition with genotoxic damage,
it is important to assess the importance of C-MYC function for DNA damage signalling in vivo. In this study, we have conditionally
deleted the c-Myc gene in the adult murine intestine and investigated the apoptotic response of intestinal enterocytes to DNA
damage. Remarkably, c-Myc deletion completely abrogated the immediate wave of apoptosis following both ionizing irradiation
and cisplatin treatment, recapitulating the phenotype of p53 deficiency in the intestine. Consistent with this, c-Myc-deficient
intestinal enterocytes did not upregulate p53. Mechanistically, this was linked to an upregulation of the E3 Ubiquitin ligase
Mdm2, which targets p53 for degradation in c-Myc-deficient intestinal enterocytes. Further, low level overexpression of c-Myc,
which does not impact on basal levels of apoptosis, elicited sustained apoptosis in response to DNA damage, suggesting c-Myc
activity acts as a crucial cell survival rheostat following DNA damage. We also identify the importance of MYC during DNA
damage-induced apoptosis in several other tissues, including the thymus and spleen, using systemic deletion of c-Myc
throughout the adult mouse. Together, we have elucidated for the first time in vivo an essential role for endogenous c-Myc in
signalling DNA damage-induced apoptosis through the control of the p53 tumour suppressor protein.
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A well-known function of the c-Myc protein is its ability to drive
apoptosis in numerous cellular contexts.1–3 Of the studies
performed, most have concentrated on the ability of c-Myc
overexpression to drive apoptosis, unless accompanied by
other mutations such as p53 loss.4 The suppression of
apoptosis is thought to be a key factor in driving tumorigenesis
in vivo, for example overexpression of c-Myc in pancreatic
islets alone does not induce tumorigenesis unless apoptosis is
blocked, for example, by p53 loss, Bcl-xl overexpression or
ARF knockout.5,6 The studies examining combined c-Myc
overexpression and p53 loss have implicated p53 directly
downstream of c-Myc, but whether this is a direct transcrip-
tional control or indirect (e.g., through c-Myc induction of the
DNA damage response) is still controversial.4 The most cited
model linking c-Myc overexpression to the p53 pathway is via
transcription induction of ARF by c-Myc, which in turn inhibits
Mdm2 (a key negative regulator of p53).7,8 Indeed, in mouse,
overexpressing high levels of c-Myc-ER from the Rosa26
locus showed that c-Myc induced apoptosis only in the colon.
This was due to higher expression of the Rosa26 locus
and hence overexpression of c-Myc-ER within the colon
compared with other tissues, leading to the induction of
ARF and apoptosis. Genetic deletion of Arf rescued this
c-Myc-induced apoptosis.9
The importance of c-Myc in signalling apoptosis following
DNA damage is poorly understood. Thus far, no study has
examined this in vivo, although in vitro studies have
suggested it may be of vital importance. There are a number
of lines of evidence for this; first (and most importantly)
Seoane et al.10 have shown that in colorectal cancer cell lines
depletion of C-MYC reduces apoptosis as a consequence of
altering the balance of downstream effectors of P53
signalling. Thus, in the absence of C-MYC, there are
increased levels of the antiapoptotic cell cycle arrest protein
P21 (a target of P53 which is also transcriptional repressed by
C-MYC in a complex with MIZ) and reduced levels of
pro-apoptotic genes such as BAX, resulting in cell cycle
arrest rather than apoptosis. Second, numerous C-MYC
transcriptional targets (either activated or repressed by
C-MYC) such as BAX, GADD45A and ONZIN have been
shown to be crucial for DNA damage signalling in vitro.11–13
Third, c-Myc has been shown to augment apoptosis in
fibroblasts following gamma irradiation.14 Finally, the post
transcriptional regulation of c-Myc through mir34 family
members has been suggested to directly impinge on c-Myc
function and the cells response to cytotoxic agents.15
With the promise of emerging cancer therapies to target
C-MYC in vivo for the first time using BET inhibitors, there is
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an urgent requirement to fully understand the role of C-MYC in
response to DNA damage. Studies by the Evan group have
shown that inhibiting endogenous murine c-Myc in vivo
through an inducible dominant negative c-Myc protein
(OMOMYC) causes regression of a variety of murine tumours
(including lung tumours induced by Kras mutation and
pancreatic neuroendocrine tumours in mice carrying the
Riptag transgene).16,17 Moreover, the effects of c-Myc loss
were well-tolerated suggesting that c-Myc is an attractive
therapeutic target. These data were consistent with our
previous studies demonstrating that c-Myc was absolutely
required for the phenotypes associated with deletion of Apc,
although the normal intestine could proliferate without c-Myc
(albeit at lower levels).18
One of the most tractable systems for studying the DNA
damage response in vivo is the intestinal crypt. Previously,
numerous cytotoxic agents such as cisplatin, ionizing radia-
tion and N-methyl-N-nitrosourea have been shown to induce
apoptosis with a peak induction normally 6–12 h following
DNA damage.19,20 This early wave of apoptosis is completely
dependent on the nuclear accumulation of p53. The tract-
ability of this system in conjunction with the our previous data
showing that c-Myc deletion is not immediately deleterious to
intestinal enterocytes makes this an ideal system to determine
whether c-Myc is important for signalling apoptosis in normal
cells following DNA damage.18 Importantly, neither of the two
studies that conditionally deleted c-Myc from the normal
intestine has seen any changes in the physiological levels of
apoptosis, which could have possibly confounded any
analysis.18,21 Both studies showed that c-Myc-deficient
enterocytes could proliferate; however, our study showed
that both the level of proliferation and cell size were reduced
compared with wild-type intestinal enterocytes.
In this study, we show that c-Myc is essential for the
induction of apoptosis within the intestinal crypt due to the
inability of c-Myc-deficient cells to efficiently upregulate p53.
Mechanistically, this is associated with high levels of Mdm2 in
MYC-deficient cells, and treatment with the MDM2 inhibitor
Nutlin restored the stabilization of p53 and induced apoptosis.
Importantly, subtle deregulation of c-Myc also has a marked
impact on the apoptotic response following DNA damage but
no effect on the normal intestine. We also find that other radio-
sensitive tissues show a dependence on c-Myc for DNA
damage-induced apoptosis. Thus, we propose a general
requirement for c-Myc expression in making cells permissive
to DNA damage-induced apoptosis in vivo.
Results
c-Myc-deficient crypts do not undergo apoptosis
following treatment with DNA-damaging agents. We first
examined whether c-Myc deletion could alter the DNA
damage response to ionizing radiation. To induce Cre-
mediated gene deletion, AhCreþ Mycfl/fl mice and control
AhCreþ Mycþ /þ mice were given three injections IP of
80 mg/kg b-naphthoflavone within a single day. This protocol
leads to near constitutive levels of c-Myc deletion from
the intestinal epithelium 4 days following Cre induction18
(Supplementary Figure 1a). At this stage, no Cre recombi-
nase expression can be detected (gene loss remains as the
deletion event occurs within the stem cell population at the
base of the crypts).22 AhCreþ Mycfl/fl mice and control
AhCreþ Mycþ /þ mice were then exposed to 14 Gray (Gy) of
gamma irradiation, and the induction of apoptosis was
scored 6 h following the irradiation.
As has previously been reported, H&E analysis of wild-type
mice showed a clear induction of apoptosis following 14 Gy
gamma irradiation compared with their nonirradiated litter-
mates (Figures 1a and b).19,20 However, the number of
apoptotic figures was significantly reduced in c-Myc-deficient
crypts given the same dose of irradiation (Figures 1a and b).
Indeed, the level of apoptosis in these crypts was closer to
nonirradiated controls than irradiated wild-type crypts
(Figure 1b). The reduction in apoptosis was not explained
due to c-Myc-deficient crypts having fewer cells than wild
type,18 as we also observed a decrease in the percentage of
crypt cells undergoing apoptosis upon c-Myc deletion
(Supplementary Figure 1b). To confirm the scoring of
apoptosis on H&E sections, immunohistochemistry (IHC)
was performed against cleaved (‘active’) caspase 3,23 and
once again the number of caspase 3-positive cells was
significantly lower in irradiated c-Myc-deficient crypts when
compared with wild-type mice given the same dose of gamma
irradiation (14 Gy) (Figures 1c and d). To extend this analysis
beyond a single time point, we next scored apoptosis at a
series of different times following gamma irradiation and
found significantly lower levels of apoptosis at all time
points subsequent to 2 h in c-Myc-deficient intestinal crypts
(Figure 1e).
The resistance to apoptosis of c-Myc-deficient enterocytes
was not restricted to high doses of g irradiation, as apoptosis
following either a lower dose of irradiation (5 Gy) or cisplatin
treatment was also found to be c-Myc dependent (Figures 1f
and g). This failure to undergo apoptosis was not simply
because c-Myc-deficient cells were not cycling, as we and
others have previously shown that c-Myc-deficient intestinal
enterocytes can undergo proliferation.18
c-Myc-deficient enterocytes do not upregulate p53. The
phenotype of c-Myc deletion paralleled the well-established
phenotype of p53 deficiency in the intestine, namely a strong
suppression of the immediate wave of apoptosis.20,24,25
Taking this information with previous data suggesting direct
links between c-Myc and p53, we investigated the kinetics of
p53 induction in the murine small intestine.3 Using immuno-
histochemistry and western blot, we observed a sharp rise in
p53 levels following gamma irradiation that is attenuated in
c-Myc-deficient crypts (Figures 2a and b and Supplementary
Figure 2a). Therefore, this provided a ready mechanism for
the abrogated apoptosis.
An alternative mechanism for failed apoptosis is that
deletion of c-Myc causes a derepression of p21, which could
also block apoptosis in this system.10,26 We and others have
previously shown that c-Myc deficiency alone is not sufficient
to trigger p21 upregulation in the intestine, however, following
combinedApc and c-Myc deletion a clear induction of p21 was
observed.18,27,28 Following irradiation (despite the reduced
p53 activation), p21 was still upregulated in c-Myc-deficient
intestinal enterocytes (Figures 2a and b and Supplementary
Figure 2b). To determine whether the lack of transcriptional
MYC is required for P53-induced apoptosis in vivo
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Figure 1 MYC-deficient crypts do not undergo apoptosis following treatment with DNA-damaging agents. (a) H&E staining of wild type (AhCreþ Mycþ /þ ) and MYC
deficient (AhCreþ Mycfl/fl) intestines 6 h following 14 Gy irradiation, arrows show apoptotic figures in wild-type mice. Scale bars¼ 50mm. (b) Scoring of apoptotic figures from
H&E sections shows a significant decrease in apoptosis in MYC-deficient mice following 14 Gy irradiation compared with wild type (* Wt versus Wt þ 14 Gy, P ¼ 0.04, Mann
Whitney n¼ 3 versus 6, ** Wt þ 14 Gy versus Myc þ 14 Gy, P ¼ 0.0041, Mann Whitney n¼ 6 versus 5). (c) Immunohistochemical staining for cleaved (‘active’) Caspase 3
was performed on intestinal sections of wild type and MYC-deficient mice. Scale bars¼ 50mm. (d) Quantification of these sections revealed a significant decrease in the
number of Caspase-3-positive cells in MYC-deficient mice following 14 Gy irradiation compared with wild type (* Wt versus Wt þ 14 Gy and Wt þ 14 Gy versus Myc þ
14 Gy, P¼ 0.04, Mann Whitney n¼ 3) (e) Graph showing that MYC is essential for the induction of apoptosis following 14 Gy irradiation. Each time point represents at least
three mice, illustrating significantly lower levels of apoptosis in MYC-deficient mice at all time points after 2 h (* wt versus Myc, P¼ 0.04, Mann Whitney n¼ 3. Error bars are
S.D.). (f) Scoring of apoptotic figures from H&E sections shows a significant decrease in apoptosis in MYC-deficient mice compared with wild type following lower levels of
irradiation (5 Gy) (* wt versus Myc, P¼ 0.04, Mann Whitney n¼ 3). (g) Scoring of apoptotic figures from H&E sections shows a significant decrease in apoptosis in
MYC-deficient mice following 10 mg/kg cisplatin treatment compared with wild type (* wt versus Myc, P¼ 0.04, Mann Whitney n¼ 3)
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repression of p21 by c-Myc was sufficient to block apoptosis,
we intercrossed p21 knockout mice to mice carrying the
Ah Cre transgene and loxP-flanked Myc alleles to generate
AhCreþ Mycfl/fl P21 / mice. Cre was induced in these mice
as described above, and these mice were irradiated 4 days
after Cre induction and apoptosis was scored 6 h following
Wt Unirradiated Wt 6h post 14Gy Mycfl/fl 6h post 14Gy
P53
Wt
Mycfl/fl
6 hours post 14 Gy nitalpsiCtsopsruoh6yG41tsop.nim03Unirradiated
γ
-
H
2A
X
 IH
C
P21
Wt
+ 14Gy
Myc fl/fl
Mycfl/fl Unirradiated
Wt Myc fl/fl
Wt
+ IR
Myc fl/fl
+ IR
P53
β-actin
Wt Myc fl/fl
Wt
+ IR
Myc fl/fl
+ IR
P21
β-actin
Myc fl/flP21-/-
+ 14Gy
P21-/-
+ 14Gy + 14Gy
8
6
4
2
A
p
o
p
to
ti
c 
b
o
d
ie
s 
/c
ry
p
t
10
0
Figure 2 Myc deletion prevents P53 accumulation after DNA damage. (a) IHC for P53 or P21 in wildtype (AhCre Mycþ /þ ) or MYC-deficient (AhCre Mycfl/f) mice 6 h
after 14 Gy g-irradiation. Note the induction of nuclear P53 following irradiation in wild-type mice that is attenuated in MYC-deficient enterocytes, and the upregulation of P21
following irradiation in both wild type and MYC-deficient enterocytes. Scale bars¼ 50mm. (b) Immunoblotting shows a marked increase in P53 levels following irradiation that
is not seen in MYC-deficient intestinal extracts (top panels). Immunoblotting shows a marked increase in P21 levels following irradiation in both wild type and MYC-deficient
intestinal extracts (bottom panels). (c) Scoring of apoptotic cells per crypt on the genotypes indicated 6 h after exposure to 14 Gy. AhCreþ Mycfl/fl P21 / mice display the
same lack of apoptotic response to 14 Gy irradiation as the MYC-deficient mice, illustrating that the induction of P21 in AhCre Mycfl/f mice is not responsible for the failure to
upregulate P53 and induce apoptosis (AhCre Mycfl/fl versus AhCreþ Mycfl/fl P21 / , P¼ 0.7656, Mann Whitney n¼ 5 versus 3). (d) Immunohistochemistry for g-H2AX in
wild-type (AhCre Mycþ /þ ) or MYC-deficient (AhCre Mycfl/f) mice following 14 Gy g-irradiation or cisplatin treatment. The large upregulation of g-H2AX 30 min after
irradiation is beginning to clear by 6 h after irradiation as DNA damage is repaired. This expression pattern is observed in both wild type and MYC-deficient crypts (and cisplatin
treated), illustrating that MYC-deficient enterocytes are able to sense DNA damage stimuli. Scale bars¼ 50mm
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14 Gy irradiation. Importantly, AhCreþ Mycfl/fl P21 / mice
displayed the same lack of apoptosis in response to irradiation
as the single c-Myc-deficient intestinal crypts (Figure 2c).
Therefore, this demonstrates that the induction of p21
following gamma irradiation was not responsible for the block
of apoptosis in c-Myc-deficient enterocytes and that reduced
p53 upregulation was the most likely cause of abrogated
apoptosis.
c-Myc-deficient enterocytes sense the DNA damage
stimuli. From the literature, there are numerous potential
mechanisms that could explain the failure to see increased
levels of p53 protein in c-Myc-deficient enterocytes. These
include failure to detect DNA damage, reduced p53 protein
stability or reduced transcription or translation of p53
mRNA.3 Therefore, we decided to test a number of these
potential mechanisms.
First, we investigated whether DNA damage recognition
was functioning in c-Myc-deficient intestinal enterocytes and
examined whether there was efficient activation of the DNA
damage sensing proteins gH2AX and ATM. This is particularly
important as it has previously been suggested that ATM is
required for c-Myc to activate p53.29 H2AX becomes
phosphorylated by ATM at the sites of double-strand breaks
in DNA and is essential for their recognition and repair.30 We
performed immunohistochemistry using an antibody that
specifically recognises the activated, phosphorylated form of
H2AX (gH2AX) to determine whether this DNA damage
response was still intact in c-Myc-deficient mice. In wild-type
mice, the level of gH2AX is markedly increased 30 min after
irradiation, and this level decreases 6 h later as DNA
damage is repaired. The activation of gH2AX following either
g-irradiation or cisplatin was also observed in MYC-deficient
intestinal enterocytes (Figure 2d). We also used an antibody
specific to the activated, serine 1981 phosphorylated form of
ATM. ATM is a regulator of cellular response to DNA damage,
and is auto phosphorylated and associates with other proteins
such as p53, Mdm2 and Chk2 to arrest cell cycle at G1. In
common with the gH2AX results, ATM is still phosphorylated
on serine 1981 in response to DNA damage in wild-type
and c-Myc-deficient mice following irradiation or cisplatin
treatment (Supplementary Figure 2c). Moreover, serine 345
phosphorylation of Chk1 that occurs downstream of ATM and
Chk2 was observed at equivalent levels in wild-type and
c-Myc-deficient intestines following irradiation or cisplatin
treatment (Supplementary Figure 2d). Taken together, these
results demonstrate that the DNA damage response is still
intact in c-Myc-deficient enterocytes and suggests that the
mechanism behind the failure to induce apoptosis in response
to DNA damage is through the control of p53 levels.
Mdm2 upregulation in c-Myc-deficient enterocytes
stops p53 accumulation and apoptosis following DNA
damage. Given the number of studies in the literature that
link c-Myc to control of p53 stability, we next investigated the
Mdm2-p53 pathway.7,8 One of the key regulators of p53
protein stability is the Mdm2 E3 ubiquitin ligase. Loss of
Mdm2 in vivo leads to embryonic death due to the activation
of high levels of p53, which can be rescued by co-deletion
of p53.31,32
First we examined the levels of Mdm2 following c-Myc
deletion by immunohistochemistry and immunoblotting. We
found a marked upregulation of Mdm in c-Myc-deficient cells
that was maintained following irradiation (Figures 3a and b).
To test whether this was functionally important for blocking
apoptosis in the c-Myc-deficient crypt cells, we employed the
Mdm2 antagonist, Nutlin-3a. Nutlin is a selective small-
molecule inhibitor of the p53-Mdm2 interaction that releases
p53 from Mdm2 control, leading to accumulation of the tumour
suppressor protein and activation of the P53 pathway.33,34
Treatment of cancer cells with wild-type P53 induces cell
arrest and apoptosis in vitro and suppresses the growth of
human tumour xenografts in nude mice.33,35
c-Myc-deficient mice were treated with Nutlin twice daily on
days 1–3 post Cre induction and a final time 3 h before 14 Gy
irradiation on day 4. This methodology was employed as it has
been shown previously that Nutlin can knockdown Mdm2 for
approximately 12 h in vivo, and a number of doses are required
for full functional inhibition.33 Apoptosis was scored in WT and
c-Myc-deficient mice 6 h following irradiation and a restoration of
the apoptotic response was observed in c-Myc-deficient mice
treated with Nutlin, though not vehicle (Figure 3c). Consistent
with previous reports, Nutlin treatment had no obvious impact on
proliferation or apoptosis of wild-type intestinal enterocytes
(either alone or treated with 14 Gy) (data not shown).35 Most
importantly, this restoration of the apoptotic response correlated
with the induction of p53 in the c-Myc-deficient mice treated with
Nutlin (Figure 3d). These data demonstrate that restoration of
p53 function, via Nutlin treatment, is sufficient to rescue the
blocked apoptosis phenotype in c-Myc-deficient enterocytes
and therefore establishes that c-Myc regulates apoptosis via
p53 in the mammalian intestine.
Deregulated overexpression of c-Myc increases and
sustains DNA damage-induced apoptosis. Our data
demonstrate that MYC loss of function completely abrogates
the apoptotic response induced by DNA damage. We next
asked if subtle overexpression of c-Myc could influence the
DNA damage response. To alter c-Myc levels, we used mice
where the c-Myc cDNA has been targeted in the ROSA26
locus and is under the control of Cre expression through Lox
Stop Lox elements in the promoter (ROSA-Floxed-Stop
(RFS)-mycWT).36 This system permits inducible, relatively
low level, deregulated c-Myc overexpression, previously
shown to be sufficient to overcome the reduced proliferation
in c-Myc-deficient intestines.37
Following activation of c-Myc transgene expression, we
induced DNA damage using 5 Gy IR and examined the impact
of increasing levels of c-Myc for the apoptotic response. This
lower level of DNA damage permits observations over
extended time points. Increasing c-Myc levels had no impact
on the basal levels of apoptosis (Figures 4a and b, 0 h time
point). Following irradiation, however, the peak apoptotic
response at 6 h was significantly increased (Figures 4a and b).
In addition, whereas in control mice the rate of apoptosis had
dropped sharply 24 h after DNA damage, it was maintained
at a significantly higher level in intestines expressing
deregulated c-Myc (Figures 4a and b). To confirm these
observations, immunohistochemistry against active caspase 3
was performed. In line with the histological data, increased
MYC is required for P53-induced apoptosis in vivo
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c-Myc levels led to increased numbers of caspase 3-positive
cells (Figures 4a and c). Thus, in addition to being required for
intestinal apoptosis following DNA damage, deregulated c-Myc
expression can also elevate and maintain it. These data
strongly suggest that the precise regulation of c-Myc levels is
important for the kinetics of apoptosis following DNA damage.
Loss of c-Myc throughout the adult mouse prevents
DNA damage-induced apoptosis in radiosensitive
tissues. Given therapeutic inhibition of C-MYC would likely
suppress its function throughout the body, we next tested if
our findings extended beyond the intestinal epithelium.
Outside of the small intestine other radiosensitive tissues
include the colon, spleen and thymus. Importantly, the adult
thymus proliferates at a very low rate, and thus this is an
excellent tissue to study the induction of p53-dependent
apoptosis that is uncoupled from proliferation. The ubiqui-
tously expressed RosaCreER permits conditional gene
deletion in multiple tissues. To test recombination rates, we
generated RosaCreERþ Lox-stop-lox RFP mice and induced
them with tamoxifen. High levels of RFP expression were
observed in multiple tissues including the colon, spleen and
thymus indicating successful recombination in these tissues
(Supplementary Figures 3a–c). To test if c-Myc is a critical
mediator of apoptosis in these tissues, we induced control
RosaCreERþ Mycþ /þ and experimental RosaCreERþ
Mycfl/fl mice, irradiated them with 14 Gy 6 days post induction
and killed them 6 h later. In the colonic epithelium, we
observed significantly decreased levels of apoptosis (Figures
5a and b) that was coincident with loss of c-Myc protein
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Figure 3 Myc deletion causes an accumulation of MDM2. (a) MDM2 IHC showing no expression in intestinal crypts of wild type (AhCre Mycþ /þ ) and a large increase of
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(Supplementary Figure 3d). As before, we confirmed this
observation with caspase 3 staining (Figures 5c and d).
Scoring of caspase 3 positivity also indicated a significantly
reduced apoptotic response in both the spleen and thymus
(Figures 5e and h). Similar to the small intestine, we
observed attenuated p53 induction in the spleen and thymus
indicating that c-Myc-dependent upregulation of p53 may be
responsible for the induction of apoptosis in multiple tissues.
(Supplementary Figure 4a and b). Interestingly, despite
a failure to induce apoptosis, p53 induction was compa-
rable between WT and c-Myc-deficient colonic cells
(Supplementary Figure 4c). This indicates that, in the colon,
c-Myc either controls apoptosis downstream of p53
signalling or via a P53-independent mechanism. Together,
these data demonstrate that c-Myc function is required for
DNA damage-induced apoptosis in multiple epithelial and
lymphoid tissues, strongly suggesting that it is a general
mediator of apoptosis in vivo.
Discussion
Here, we demonstrate for the first time in an in vivo setting that
endogenous c-Myc is required for efficient induction of
apoptosis following DNA damage. We show that this is due
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Figure 5 MYC deletion prevents DNA damage-induced apoptosis in multiple tissues. (a) H&E staining of wild type (RosaCreERT2 Mycþ /þ ) and MYC-deficient
(RosaCreERT2 Mycfl/fl) colons 6 h following 14 Gy irradiation, arrows show apoptotic bodies. Scale bars¼ 50mm. (b) Scoring of apoptotic bodies from H&E sections shows a
significant decrease in apoptosis in MYC-deficient colons following 14 Gy irradiation compared with wild type (** wt versus Myc, P¼ 0.0059, Mann Whitney n¼ 5 versus 7).
(c) Caspase 3 IHC staining of wild type (RosaCreERT2 Mycþ /þ ) and MYC-deficient (RosaCreERT2 Mycfl/fl) colons 6 h following 14 Gy irradiation, arrows indicate Caspase
3-positive cells. Scale bars¼ 50mm. (d) Scoring of Caspase 3-positive cells (percentage of total cells: n4500) shows a significant decrease in apoptotic cells in
MYC-deficient colons (** wt versus Myc, P¼ 0.0059, Mann Whitney n¼ 5versus7). (e) Caspase 3 IHC staining of wild type (RosaCreERT2 Mycþ /þ ) and MYC-deficient
(RosaCreERT2 Mycfl/fl) spleens 6 h following 14 Gy irradiation, arrows indicate Caspase 3-positive cells. Scale bars¼ 50mm. (f) Scoring of Caspase 3-positive cells
(percentage of total cells: n4500) shows a significant decrease in apoptotic cells in MYC-deficient spleens (* wt versus Myc, P¼ 0.0152, Mann Whitney n¼ 4). (g) Caspase 3
IHC staining of wild type (RosaCreERT2 Mycþ /þ ) and MYC-deficient (RosaCreERT2 Mycfl/fl) thymus 6 h following 14 Gy irradiation, arrows indicate Caspase 3-positive cells.
Scale bars¼ 50mm. (h) Scoring of Caspase 3-positive cells (percentage of total cells: n4500) shows a significant decrease in apoptotic cells in MYC-deficient thymus
(* wt versus Myc, P¼ 0.0152, Mann Whitney n¼ 4)
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to a failure to upregulate p53 owing to increased levels of the
E3 ubiquitin ligase Mdm2 (Figure 6). As this mechanism is
conserved in multiple tissues, we contend that c-Myc serves
as a universal regulator of apoptosis in vivo.
c-Myc has the ability to sensitize or induce apoptosis
in vitro, but its role in this process is not well established
in vivo. We found that deletion of c-Myc throughout the adult
mouse strongly suppressed the apoptotic response following
DNA damage. c-Myc-deficient intestinal epithelial cells are
able to proliferate and thymocytes proliferate very slowly,
thus the lack of apoptosis is not simply a byproduct of the
proliferative function of c-Myc. Indeed, as overexpression of
c-Myc in the small intestine increased both the level and
length of the apoptotic response, we believe c-Myc should be
regarded as an apoptotic permissivity factor. Thus, it is also
likely that the precise regulation of c-Myc throughout DNA
damage-induced apoptosis is important for the cessation of
the apoptotic response following DNA repair. Interestingly,
subtle deregulation of c-Myc expression did not lead to
increased levels of intestinal apoptosis in the absence of
DNA damage. This appears to contrast with previous studies
demonstrating that overexpression of c-Myc-ER leads to
ectopic apoptosis in the colon.9 This may be due to a
difference in apoptotic response between the small intestine
and colon. Alternatively, it may highlight a difference
between overexpression of c-Myc-ER and c-Myc. It is
possible that c-Myc-ER accumulates to high levels in the
absence of tamoxifen. Thus, when tamoxifen is adminis-
tered, the acute burst of c-Myc-ER activity induced is
sufficient to drive apoptosis. As c-Myc expression is
regulated by multiple transcriptional and post transcriptional
mechanisms in vitro, it is likely that its regulation in vivo is
also complex.38 It is interesting to note that previous studies
have shown that reducing the c-Myc targeting mir34b/c
microRNA causes increased DNA damage apoptosis,
suggesting physiological regulation of c-Myc levels following
DNA damage modifies the apoptotic response.15
We observed a failure to induce p53 in Myc-deficient
intestinal, splenic and thymic cells. In the intestine, this was
associated with increased Mdm2 expression and treatment
with the Mdm2 inhibitor Nutlin rescued both p53 activation and
induction of apoptosis. This suggests that c-Myc regulates
apoptosis via post translational regulation of p53 stability
in vivo. ATM can also activate p53 suggesting that failed DNA
damage signalling could also impact on apoptotic response.29
Importantly, we found DNA damage signalling intact in
c-Myc-deficient intestines indicating that control of Mdm2 is
the primary mechanism through which c-Myc regulates
apoptosis in vivo. The precise mechanism linking c-Myc
levels to Mdm2 expression is unclear, but Mdm2 has
previously been shown to be a direct transcriptional target of
NMYC in neuroblastoma.39 Although this study demonstrated
a role in activating Mdm2 transcription, c-Myc proteins are
also well-defined transcriptional repressors so it is tempting to
speculate that Mdm2 transcription may be directly inhibited by
c-Myc. Alternatively, the c-Myc transcriptional target Nucleolin
has been shown to directly bind to and inhibit Mdm2.40 This
binding was also shown to lead to reduced levels of Mdm2
protein, thus making it an attractive potential mediator of the
phenotypes we observe. A thorough dissection of these
potential interactions will be important for further under-
standing of this process.
Interestingly, it does not appear that this mechanism
extends to the colon as c-Myc-deficient colonic cells efficiently
upregulate P53 following irradiation. This indicates that
induction of the apoptotic programme, although c-Myc
dependent, is fundamentally different in the colon. With
regards to this, the transcriptional activation and oligomeriza-
tion of the apoptosis regulator Bax has been shown to be
controlled by c-Myc.11,41 Thus, it is possible that colonic cells
engage a different apoptotic programme from those in the
intestine. Determining the mechanistic basis for this differ-
ence will be an interesting future avenue of research.
C-MYC is one of the most commonly altered genes in
human cancer with gene amplifications and transcriptional
activation especially common. As such, it is a very attractive
therapeutic target and several recent studies have highlighted
this potential. In particular, c-Myc inhibition using a dominant
negative form of the protein termed OMOMYC was shown to
regress tumours from both lung and pancreatic mouse tumour
models.16,17 Importantly, although expression of OMOMYC
suppressed proliferation in various tissues, these effects were
completely reversed upon cessation of treatment. This
suggests that C-MYC inhibition would not be overly toxic
and is therefore a viable therapeutic target. Inhibition of BET
bromodomain proteins has been shown to inhibit C-MYC
function and tumorigenesis, thus chemical suppression of
MYC may be possible.42 As most C-MYC inhibitory agents
would be delivered alongside DNA-damaging agents, our
findings that c-Myc is required for apoptosis are important. It
will be important to determine if our findings extend to
tumorigenic cells as they may also be protected from
apoptosis by C-MYC inhibition. If this is the case then precise
coordination of treatment regimens may be required to
achieve maximum functionality. Interestingly, OMOMYC or
BET inhibition both lead to proliferation arrest and apoptosis in
transformed cells, indicating that they may not have the same
requirement for C-MYC during apoptosis. In fact, this may
lead to an unexpected benefit of C-MYC inhibition, namely
MDM2
MYC
P53
Normal tissue MYC deficient tissue
MYC
MDM2
P53
sisotpopa oNsisotpopA
Figure 6 Model of MYC regulation of apoptosis in response to DNA damage in
the intestine. (a) In wild type, MYC-proficient mice, the intestinal epithelial cells
respond to DNA damage by upregulating MYC, which then inhibits MDM2. This
allows P53 levels to increase and induce apoptosis. (b) When MYC is deleted from
the intestinal epithelial cells they can no longer inhibit MDM2 in response to DNA
damage, and consequently P53 is not upregulated resulting in reduced apoptosis
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some protection from the side effects of commonly used
therapeutics. It will be important to gain further understanding
of this process in vivo to help better understand this issue.
In conclusion, we have demonstrated for the first time, a
requirement for c-Myc function during the induction of
apoptosis following DNA damage. We find this function is
constant in multiple tissues defining c-Myc as a general
mediator of apoptosis in vivo.
Materials and Methods
Mouse experiments. All experiments were performed under the UK Home
Office guidelines. Outbred male mice from 6 to 12 weeks of age were used, which
were segregating for the C57BLJ and S129 genomes. The alleles used were as
follows: Mycfl, AhCre, P21, ROSA-Floxed-Stop (RFS)-mycWT, RosaCreER and
ROSA-tdRFP.22,36,43–47 Myc experiments were also confirmed on mice that had
been backcrossed to C57Bl6J for five generations.
Cre induction was carried out by giving AhCreþ Mycþ þ and AhCreþMycfl/fl
3 intraperitoneal (IP) injections of 80 mg/kg b-naphthoflavone in a single day. Mice were
then given DNA damage 4 days after induced gene deletion. Previous experiments
have shown that, using this protocol, no significant induction of apoptosis is seen in
induced (AhCreþ Mycþ þ ) when compared with uninduced AhCreþ Mycþ þ or
induced wild type (mice not carrying the AhCre transgene) at day 4 after induction.
For assessing whether MYC deficiency affects the DNA damage response
following gamma irradiation ‘wild type’ AhCreþ Mycþ þ and MYC-deficient
AhCreþ Mycfl/fl mice were irradiated with 14 Gy irradiation using a Cs137 source
delivered at a dose rate of at 0.423 Gy/min. Mice were then collected at 30 min, 1, 2,
3, 6, 12, 24 and 48 h time points following the irradiation. At least three mice were
used for each time point. For cisplatin treatment, mice were given a single IP
injection of 10 mg/kg Cisplatin (purchased from David Bull Laboratories (Warwick,
UK) and distributed by Faulding Pharmaceuticals).
For assessing whether MDM2 upregulation abrogated apoptosis following
Myc deletion, ‘wild-type’ AhCreþ Myc/þ þ and Myc-deficient AhCreþ Mycfl/fl
mice were gavaged with either 200 ml of vehicle or 200 mg/kg nutlin-3a
(synthesized at the Roche Research Center, Nutley, NJ, USA) twice a day as
previously described.33 On day 4 post Cre induction, mice were given a single
application of nutlin and irradiated with 14 Gy and collected 6 h following the
irradiation.
Tissue isolation. Tissue isolation was carried out as follows: the proximal
7 cm was fixed overnight in methacarn (methanol, chloroform and acetic acid;
4 : 2 : 1) and then paraffin embedded. The following 3 cm was preserved in RNA
later (Sigma, Gillingham, UK). The following 5 cm was bundled using surgical tape
and fixed in 4% formaldehyde at 4 1C for 24 h before processing. The remainder
was fixed in methacarn.
Assaying apoptosis in vivo. Apoptotic bodies were scored from H&E
sections. Twenty-five full crypts were scored from a minimum of three mice of each
genotype. Apoptosis was confirmed by immunohistochemical staining against
active caspase 3 (1:750, R&D systems, Abbingdon, UK).
Immunohistochemistry. Primary antibodies used for immunohistochemistry:
P21 (1 : 500, Santa Cruz, Dallas, TX, USA; M19), P53 (1 : 100 MS-104, PAB240
Neomarkers) and P53 (VectorLabs, Peterborough, UK; CM5), CHK1 pS345
(1 : 100, Cell Signalling, Danvers, MA, USA), ATM pS1981 (1 : 500, ROCKLAND
200-301-500), MDM2 (1 : 200, Lab Vision, Waltham, MA, USA; smp14 ms- 291-p1),
g-H2AX (1 : 300 Upstate), MYC (1 : 500, Santa Cruz, N-262, sc764).
Epithelial extractions. To obtain a population of epithelial cells, an epithelial
extraction protocol based on Bjerknes & Cheng48 was performed. In brief, 10 cm of
small intestine was flushed with water before being tied and everted over a glass rod.
Vibration was then applied, and the intestine placed in 10 mM EDTA in Hanks’
Balanced Salt Solution (HBSS; Gibco, Paisley, UK) at 37 1C for 15 min. The intestine
was moved into a fresh tube of 10 mM EDTA/HBSS and incubated for a further
15 min. Epithelial cells were collected by centrifugation (2700 g, 4 1C, 15 min).
Western blot analysis. Protein was extracted from epithelial extracted
samples by standard methods using lysis buffer (20 mM Tris-Hcl pH8.0, 2 mM
EDTA (pH8.0), 0.5% (v/v) NP-40) containing protease inhibitors (Complete Mini
Protease inhibitor tablets, Roche, Burgess Hill, UK) and phosphatase inhibitors
(25 mM sodium b-glycerophosphate, 100 mM sodium fluoride, 20 nM Calyculin A,
10 mM sodium pyrophosphate). Solubilised proteins (20 mg) were separated by
standard SDS-PAGE on a 10% polyacrylamide separating gel with 5% stacking
gel and subsequently transferred to PVDF membrane (Hybond-P, Amersham
Biosciences, Buckinghamshire, UK) by standard methods. Primary antibodies and
conditions used to probe blots were rabbit anti-MDM2 (1 : 1000; R&D systems
AF1244), mouse anti-P53 (1 : 1000; Cell Signalling Technology 1C12), rabbit
anti-P21 (1 : 200; Santa Cruz sc479) and mouse anti-b-actin (1 : 5000; Sigma).
Appropriate HRP-conjugated secondary anti-rabbit or anti-mouse antibodies were
used (Amersham Biosciences).
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